Centerpoint Advisors’s GSK GSK Stock Holding History

Centerpoint Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-152	Closed	-$7K	–	424
2025 Q3	$7K	Buy	+152	New	+$5.94K	﹤0.01%	348
2024 Q3	–	Sell	-392	Closed	-$15K	–	476
2024 Q2	$15K	Hold	392	–	–	0.01%	311
2024 Q1	$17K	Hold	392	–	–	0.01%	277
2023 Q4	$15K	Sell	392 -454	-54%	-$16.3K	0.01%	294
2023 Q3	$31K	Hold	846	–	–	0.01%	184
2023 Q2	$30K	Hold	846	–	–	0.01%	202
2023 Q1	$30K	Buy	846 +454	+116%	+$15.9K	0.01%	209
2022 Q4	$14K	Hold	392	–	–	0.01%	261
2022 Q3	$12K	Hold	392	–	–	0.01%	208
2022 Q2	$21K	Hold	392	–	–	0.01%	186
2022 Q1	$21K	Hold	392	–	–	0.01%	190
2021 Q4	$22K	Buy	+392	New	+$20.4K	0.01%	177
2018 Q3	–	Sell	-579	Closed	-$29K	–	291
2018 Q2	$29K	Buy	+579	New	+$29.2K	0.02%	123

Other funds holding GSK

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Centerpoint Advisors's GSK Position: Q4 2025 in Review

Centerpoint Advisors sold out of GSK (GSK) in Q4 2025, closing a stake of 152 shares — an estimated $7K sold.

Centerpoint Advisors first reported a position in GSK in Q2 2018 and held it in 13 quarters. The position peaked at $31K in Q3 2023. 997 funds tracked by Wall St. Rank hold GSK as of Q4 2025.

Centerpoint Advisors reported no remaining GSK position as of Q4 2025 after selling out during the quarter.
Centerpoint Advisors sold 152 GSK shares in Q4 2025, an estimated $7K.
Centerpoint Advisors first reported a position in GSK in Q2 2018 and held it in 13 quarters.
Centerpoint Advisors's GSK position peaked at $31K in Q3 2023.
997 funds tracked by Wall St. Rank held GSK as of Q4 2025.

Based on Centerpoint Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.